RxDoctor Payments DataLook up a doctor →

Charlotte-Paige Rolle, MD

Infectious Disease · Orlando, FLNPI 1023338878

Payments from drug & device makers

$6,031,063in general payments, 2019–2025

Across 1,093 payments — averaging $5517.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2.6M
  • Gilead$1.7M
  • GSK$471K
  • AbbVie$462K
  • Merck$452K
  • Theratechnologies Inc.$316K
  • plus $48K from 7 others
$1,803in research payments, 2019–2025

Across 18 payments — averaging $100.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Viiv Healthcare Company$957
  • GSK$847

What the payments were for

  • Consulting fees$185,77030%
  • Speaking & faculty fees$398,52264%
  • Travel & lodging$21,5333%
  • Food & beverage$12,6902%
  • Education$110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,031,063 in reported general payments places this provider in the 95th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$10,827
Medicare patients
48
Services billed
97

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala203$800,175
TrogarzoIbalizumab-Uiyk62$730,105
RukobiaFostemsavir Tromethamine36$317,612
CabenuvaCabotegravir/Rilpivirine23$150,939
TivicayDolutegravir Sodium66$148,205
DovatoDolutegravir Sodium/Lamivudine46$137,783
PifeltroDoravirine72$131,280
OdefseyEmtricitab/Rilpiviri/Tenof Ala21$82,186
DescovyEmtricitabine/Tenofov Alafenam29$63,750
TriumeqAbacavir/Dolutegravir/Lamivudi11$45,080
IsentressRaltegravir Potassium18$37,477
PrezistaDarunavir11$24,669
Darunavir18$20,863
Ritonavir26$3,882
ValacyclovirValacyclovir Hcl15$2,156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$1,727,009$863,925232 claims
Viiv Healthcare CompanyRukobia, Cabenuva, Tivicay, Dovato, Triumeq$2,554,668$799,620182 claims
Theratechnologies Inc.Trogarzo$315,531$730,10562 claims
MerckPifeltro, Isentress$452,141$168,75790 claims
Janssen Scientific Affairs, LLCPrezista$6,951$24,66911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →